Anti-TNFR1 [Nb70]
Catalogue Number: AB04109-34.11-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | TNFRI; Tumor necrosis factor RI; Tumor necrosis factor R1; Tumor necrosis factor receptor type 1-associated death domain protein; TNFR1-associated death domain protein; TNFRSF1A-associated via death domain; Nb 14; Nanobody 14 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 500 ug |
| Host name: | Camelid |
| Clone: | Nb70 |
| Isotype: | |
| Immunogen: | The original antibody was generated by immunizing an alpaca (Vicugna pacos) with soluble human TNFR1 (hTNFR1). A VHH library was constructed using total RNA from peripheral blood lymphocytes, and panning on hTNFR1 was performed to isolate antigen-specific nanobodies. |
| Application: | ELISA, FA, InVivoA, SPR |
Additional Text
Gene ID
8717
Gene Name
TRADD
Uniprot ID
Q15628
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Application Notes
The original format of this antibody (VHH) was used in ELISAs to determine its binding affinity to soluble human TNFR1 (hTNFR1) and other proteins such as albumin, human TNFR2 (hTNFR2), and mouse TNFR1 (mTNFR1); a KD of 7.709 nM was measured for hTNFR1. This antibody was tested in a HEK-2 Blue assay to evaluate its inhibitory effect on the signaling of human TNF (hTNF) through TNFR1; it was found to effectively inhibit hTNFR1 by competing with TNF for binding with an IC50 value of 4.144 µM and with lymphotoxin alpha (LTa) with an IC50 of 220 nM. This antibody's affinity for hTNFR1 was evaluated by SPR analysis; a KD of 38.71 nM was measured. This antibody was used to create a trivalent nanobody by linking it to clones Nb 96 and Nb Albumin using flexible [G4-S]3 linkers, and the resulting nanobody (Nb Alb-70-96) - TNF Receptor-One Silencer (TROS) - was tested for various in vitro, in vivo, and ex vivo (Steeland et al., 2015; PMID: 25538244). The original antibody format was used to create another trivalent nanobody by linking it to clones Nb 14 and Nb Albumin using the same linkers, and the resulting nanobody (Nb 70-Alb-14) was used in vivo to study the effects of inhibiting matrix MMP8 and TNFR1 in sepsis using endotoxemia and CLP (cecal ligation and puncture; a surgical procedure commonly used in animal models to induce polymicrobial sepsis) experimental models (Steeland et al., 2018; PMID: 29095202).
AB04109-34.11-BT Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations